DOI: 10.1155/2023/6669174 ISSN: 2090-6579
Epstein–Barr Virus Driven Hodgkin’s Lymphoma after a Short Course of Daratumumab Treatment for Relapsed Multiple Myeloma
Moeen Mohammadi-Oroujeh, Ansa Mehreen, David L. Grinblatt- Cell Biology
- Developmental Biology
- Embryology
- Anatomy
In this case, we describe the potential risk of developing an infectious complication leading to a secondary malignancy after a short course of immunotherapy. We report a patient who presented with Epstein–Barr virus (EBV) driven Hodgkin’s lymphoma after treatment with a short course of daratumumab along with pomalidomide and dexamethasone for relapsed multiple myeloma. Although there have been limited documented cases of daratumumab treatment leading to EBV reactivation, in patients presenting with infectious symptoms or neutropenia on a daratumumab-based regimen, testing for EBV should not be overlooked.